CureVac Acquisition Finalized as BioNTech Secures Controlling Stake

CureVac NL0015436031

The fate of CureVac’s independent stock market journey has been sealed. BioNTech has successfully cleared the final hurdle for its takeover, having received tenders for a decisive majority of CureVac’s outstanding shares. This move effectively concludes CureVac’s standalone trading narrative, transitioning to a technical settlement process with significant implications for remaining shareholders.

BioNTech has formally announced that the central condition of its offer has been met. By the close of the initial acceptance period, approximately 81.74% of all CureVac shares had been tendered. This outcome makes the acquisition a fait accompli, setting in motion an irreversible integration into the BioNTech corporate structure.